Bibliographic record
Abstract
The advent of biologic therapies has revolutionized the treatment of moderate-to-severe psoriasis. With the approval of several tumor necrosis factor-alpha (TNF-a) inhibitors, interleukin 12/23 (IL-12/23) inhibitors, and IL-17 inhibitors, physicians now have multiple options when choosing which drug to prescribe to psoriasis patients. Biosimilars aim to have near-identical safety and efficacy profiles compared with their reference bio-originator products, while decreasing the overall cost. Biosimilar versions of infliximab and etanercept have been approved by the European Medicines Agency (EMA), biosimilars have been approved by Health Canada for infliximab, and the United States Food and Drug Administration (FDA) approved a biosimilar for infliximab in April 2016. Certolizumab pegol is a monoclonal Fab fragment antibody conjugated to polyethylene glycol (PEG) targeting soluble and transmembrane TNF-a. It is currently approved for psoriatic arthritis but not plaque psoriasis. Despite the efficacy and safety of the six approved biologic drugs for moderate-to-severe psoriasis, there are many novel biologic and biosimilar drugs in the pipeline.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.007 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".